AA Amyloidosis Secondary to Horton's Disease Complicated by Pulmonary Fibrosis: A Very Challenging Diagnosis and Therapy
M. Njie *
Department of Cardiology P37, Ibn Rochd University Hospital, Casablanca, Morocco.
P. M. Mulendelé
Department of Cardiology P37, Ibn Rochd University Hospital, Casablanca, Morocco.
O. Mokni
Department of Cardiology, PH, CH Jacques Monod, Normandie, France.
M. Sidi Boutar
Department of Cardiology P37, Ibn Rochd University Hospital, Casablanca, Morocco.
M. Haboub
Department of Cardiology P37, Ibn Rochd University Hospital, Casablanca, Morocco and Department of Cardiology, Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco.
S. Arous
Department of Cardiology P37, Ibn Rochd University Hospital, Casablanca, Morocco and Department of Cardiology, Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco.
M. Ghali Benouna
Department of Cardiology P37, Ibn Rochd University Hospital, Casablanca, Morocco and Department of Cardiology, Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco.
A. Drighil
Department of Cardiology P37, Ibn Rochd University Hospital, Casablanca, Morocco and Department of Cardiology, Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco.
L. Azzouzi
Department of Cardiology P37, Ibn Rochd University Hospital, Casablanca, Morocco and Department of Cardiology, Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco.
R. Habbal
Department of Cardiology P37, Ibn Rochd University Hospital, Casablanca, Morocco and Department of Cardiology, Faculty of Medicine and Pharmacy, Hassan II University of Casablanca, Casablanca, Morocco.
*Author to whom correspondence should be addressed.
Abstract
AA amyloidosis is a classic and serious complication of many chronic inflammatory processes, whether of infectious, autoimmune, or neoplastic origin. It is frequently complicated by kidney damage, often in the form of a nephrotic syndrome. Giant cell arteritis is a common inflammatory arteritis in the elderly; however, it rarely causes AA amyloidosis. We report a rare case of Horton disease causing AA amyloidosis in an elderly patient with history of myopericarditis and repeated episodes of congestive heart failure. Patient was treated initially with dual therapy based on corticosteroids and anti TNF therapy (Tocilizumab) associated with heart failure therapy recommended by the European society of cardiology (ESC 2021 guidelines on Heart Failure). The initial outcome was favorable but later complicated by the involvement of the lungs; pulmonary fibrosis, responsible for repeated episodes of pleural effusion non controlled in spite of high dose of loop diuretics and repeated pleural punction. Patient died shortly after her second hospitalization due to respiratory insufficiency.
Keywords: Horton disease, AA amyloidosis, pulmonary fibrosis, Cardiac MRI, corticosteroids and Tocilizumab
How to Cite
References
Ammouri W, Tassine H, Maghraoui A, Khibri H, Maamar M, Tazi Mezalek Z, Harmouche H, Adnaoui M. Amylose AA compliquant une maladie d’Horton traitée avec succès par du tocilizumab. Revmed. 2019;10:150
Hamelin JP, Cardon G, Reberolle M, Moulonguet F, Neugebauer Y, Raybaud G, Gnemmi V, Hachulla E. Giant cell aortitis complicated by AA amyloidosis diagnosed with imaging techniques: Report of a case. Revmed. 2016;03:009.
Bienvenu B, et al. Groupe d’étude français des artérites des gros vaisseaux (GEFA)”, under the aegis of the “Filièredes maladies auto-immunes et auto-inflammatoires rares (FAI (2)R)”. Management of giant cellarteritis: recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). Rev Med Interne; 2016.
Agard C, et al. Abdominal aortic involvement in active giant cell (temporal) arteritis: a study of 20 patients by Doppler ultrasonography and computed tomographic angiography. Presse Med; 2009.
Mekinian A, et al. Usefulness of imaging in large vessel vasculitis. Rev Med Interne; 2016.
Shuhei Yoshida, Haruki Matsumoto, Jumpei Temmoku, Norshalena Shakespear, Yuichiro Kiko, Kentaro Kikuchi, Yuya Sumichika, Kenji Saito, Yuya Fujita, Naoki Matsuoka, Tomoyuki Asano, Shuzo Sato, Eiji Suzuki, Hiroshi Watanabe,Hiromasa Ohira3 and Kiyoshi Migita.Case report: Rapid development of amyloid A amyloidosis in temporal arteritis with SAA1.3 allele; An unusual case of intestinal amyloidosis secondary to temporal arteritis. Front Immunol. 2023; 21:1144397.
Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid a protein. Lancet. 2001;358:24–9.
Delplanque M, Pouchot J, Ducharme -Bénard S, Fautrel BJ, Benyamine A, Daniel L, Gendre T, Grateau G, Georgin-Lavialle S. AA amyloidosis secondary to adult-onset Still's disease: About 19 cases. Semarthrit. 2019;50:156-165.
Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356:2361–71.
Riccardo Papa, Helen J. Lachmann. Secondary, AA, Amyloidosis. Rheum Dis Clin N Am. 2018;04:006.
Baba S, Masago SA, Takahashi T, Kasama T, Sugimura H, Tsugane S, et al. A novel allelic variant of serum amyloid a, SAA1 gamma: Genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA-amyloidosis. Hum Mol Genet. 1995;4 :1083–7.
Lyons HS, Quick V, Sinclair AJ, Nagaraju S, Mollan SP. A new era for giant cell arteritis. Eye. 2020;34:1013–1026.
Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356:2361–71.
Pamuk ON, Donmez S, Pamuk GE, Puyan FO, Keystone EC. Turkish experience in rheumatoid arthritis patients with clinical apparent amyloid deposition. Amyloid. 2013;20:245–50.
Giant cell arteritis "causing" AA-amyloidosis with rapid renal failure. Strasser F, Hailemariam S, Weinreich T, Speich R, Salomon F.Schweiz Med Wochenschr. 2000;130:1606-9.
Proven A, Gabriel SE, Orces C, O'Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: Duration and adverse outcomes. Arthritis Rheum. 2003;49: 703–8.
Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of tocilizumab in giant- cell arteritis. N Engl J Med. 2017;377:317–28.
Okuda Y, Ohnishi M, Matoba K, Jouyama K, Yamada A, Sawada N, et al. Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. Mod Rheumatol. 2014;24:137–43.
Madiha Mahfoudhi, Habiba Mamlouk, Sami Turki, Adel Kheder. Maladie de Horton révélée par une dyspnée. Pamj. 2015;20:465.
Desai HV, Aronow WS, Peterson SJ, Frishman WH. Cardiac amyloidosis: Approaches to diagnosis and management. Cardiol Rev. 2010;18:1-11.